Advertisement


Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Opening Session Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Advertisement